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The treatment of vitiligo has received active
consideration since the advent of the systemic
and topical administration of the psoralen com-
pounds. Fahmy and Shady (1, 2, 3) reported the
isolation of three crystalline principles from the
fruits Ammi Majus Linn., namely Ammoidin,
Majudin, and Ammidin. Schonberg, Sina, Fahmy
and Shady (3, 4) found these compounds to be
identical with the previously known chemicals
xanthotoxin, bergapten, and imperatorin, re-
spectively. The three compounds are psoralen
(furo-coumarin) derivatives and have the chemi-
cal designations of 8-methoxypsoralen (Am-
moidin), 5-methoxypsoralen (Majudin) and 8-iso-
amylene oxypsoralen (Ammidin).
Early in 1950 it has been reported by El-
Hefnawi (5) that the use of crystalline con-
stituents of the Ammi Majus Linn. in various
combinations (given orally and/or topically) with
exposure of the lesions to ultra-violet rays
(natural or artificial) resulted in the cure of some
of the vitiligenous patients. El-Mofty (6), Sekia
(7), and Sidi (8) confirmed these findings.
Recent investigations by El-Mofty, El-Hawary
and Farag (9), showed that with the complete
pigmentation of vitiligenous patches in patients
under oral psoralen therapy, the serum copper is
raised to normal levels. In 80% of the cases with
an original low level of serum copper, oral
psoralen caused a rise. However, El-Mofty (10)
has reported that 39.5% was the maximum per-
centage of cure in patients under treatment with
oral psoralens. It is apparent that this percentage
of cure does not parallel the high percentage of
serum copper increase after psoralen therapy.
Mann and Keilin (11), have shown that most
of the serum copper is firmly bound to protein.
Estimates of the amounts of copper bound to
albumin and to each of the major globulin
fractions have been made by Thompson and
Watson (12), Cumings, Goodwin and Earl (13).
* From the ** Department of Dermatology,Cairo University and the ***Nutrition Research
Unit, National Research Centre, Cairo, Egypt.
Received for publication April 30, 1962.
111
The results of these two studies would seem to
indicate that the amounts of serum copper
bound to serum alpha, beta and gamma globulins
comprise approximately 25, 50 and 20% re-
spectively of the total plasma copper, only
negligible amounts being attached to the serum
albumin fraction. Other workers cited by Kugel-
mass (14) and Duncan (15) have found that
serum copper is composed of two fractions, a
loosely bound fraction accounting for 5% as-
sociated with albumin, beta-globulin, transferrin,
or other plasma proteins and a firmly bound
fraction representing 95% of the total copper,
bound to serum alpha2-globulin. Gubler (16)
found the former fraction involved in copper
transport regardless of its mode of entry into the
circulation. Studies on copper metabolism by
Scheinberg et at (17) and isotopic studies with
labelled copper by Sternlieb et al (18) revealed
initial association of copper with serum albumin
fraction immediately after ingestion or injection
and subsequent combination with serum alpha2-
globulin after incorporation into ceruloplasmin.
The reviewed relations of copper to different
serum protein fractions, the findings of El-
Hefnawi et at (19, 20) of high serum copper
values, and high serum alpha2-globulin fraction
in patients with xeroderma pigmentosum and the
low serum copper in certain eases of vitiligo (28)
gave us the impetus to study the serum protein
fractions in cases of vitiligo before and after
treatment with oral psoralens and ultra-violet
irradiation of the affected areas.
MATERIAL AND METHOD
The present work deals with the study of the
levels of serum proteins and their electrophoretic
fractionation in a group of 100 cases of vitiligo.
Out of these, 77 cases could be kept under our
close observation and study throughout the whole
period of 24 months. The other 23 cases failed to
return for any follow-up although strongly urged
to do so. Vitiligenous cases studied consisted of
hospital out-patients and private patients who
did not receive any previous psoralens (local or
oral). No cases of albuminuria or glycosuria were
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included in this study. Liver diseases or disfunc-
tions were excluded by clinical and laboratory
investigations including liver function tests.
Pregnant females were excluded to avoid the
variations in serum proteins which are known to
occur according to Brown (21) and Kuhn et cl.
(22).
All patients in this study (40 females and 37
males) were treated with oral meladinine plus
ultra-violet irradiation. The ages of these persons
varied from 5—60 years. Treatment started orally
with one tablet of meladinine (10 mg ammoidin
and 5 mg ammidin) per day and the patients were
instructed to increase the dosage by one tablet
every other day until a dosage of two tablets
t.d.s. was reached and was continued unless
anorexia, nausea or any other sign of toxicity
necessitated reducing or temporarily stopping the
drug. Children were given smaller oral doses ac-
cording to their age.
The oral treatment was interrupted for one
week of each month to provide rest from the drug.
No local psoralen therapy was used in this present
study. The dosage had to be reduced to one tablet
t.d.s. in seven cases because of slight anorexia and
nausea. Children tolerated the drug markedly.
The patients were advised to expose the affected
vitiligenous areas to sun (either early or towards
sunset time i.e. oblique rays) in a place which is
dust free. They were advised to keep initial ex-
posures to light well below the time of the usual
erythema dose. They were then advised to in-
crease the exposure time gradually to tolerance.
Those patients that could not follow this system
were treated with artificial ultra-violet light from
a mercury lamp in the out-patient clinic. The pa-
tients who had extensive vitiligenous areas were
advised to avoid irradiating all the patches at one
sitting, but to divide the affected areas to be ir-
radiated successively at two day intervals. When-
ever severe erythema or vesiculation took place,
the treatment with ultra-violet rays or sun was
stopped and soothing applications were given.
Collection of Blood
Before starting the treatment the fasting venous
blood samples were collected with a dry needle
and syringe at 8 a.m. The blood was placed in a
dry test tube, allowed to clot and the serum was
then separated by centrifugation. Part of this
serum was used for the estimations of total pro-
teins and electrophoresis. The rest of the sample
was kept in a freezer for further reference.
Repeated examination of the serum proteins of
the cases after starting therapy were carried out
at 3 month intervals until complete cure and a
final test.
Treatment of cases that showed partial or no
cure was continued for a period of 24 months at
which time a final analysis of the serum proteins
was done. However, the tabulations here recorded
are the results obtained for serum protein frac-
tions before treatment, and at time of complete
cure or at the end of the period of study.
Electrophorelic Procedure
Electrophoretic separation of serum proteins
was carried out on Whatman No. 1 filter paper
strips (4 ems in width and 43 ems in length) in an
eleetrophoretic apparatus similar to that of Dur-
ram (23). 0.02 ml. of serum was applied by a micro-
pipette to the center of the filter paper strip. The
vertical method of electrophoresis was employed,
using veronal buffer of pH 8.2 and ionic strength
0.05 M. A potential gradient of 120 volts and a
current limited to 0.5 milli-ampere for each filter
paper strip was applied. The electrophoretie run
was allowed for about 16 hours. The strips, at the
end of the run, were removed from the tank,
spread fiat and fixed at their ends on two parallel
wooden bars and dried in an oven at 110° C. for
ten minutes. The dried strips were then stained
in a solution of azocarmine B (2.5 gm azocarmine
B in 500 ml. methanol, 100 ml, glacial acetic acid
and then 400 ml. water was added and the volume
made up to one liter in a volumetric flask) for ten
minutes in a flat basin. After this period the dye
was drained off and aqueous acetic acid solution
10% was used for washing the strips to get rid of
excess of the dye. Washing was repeated three
times, after which the dyed protein bands show
themselves on an almost non-stained background.
After washing, the strips were then dried and the
elution of the individual protein bands was per-
formed using N/10 sodium hydroxide. The pro-
teins on filter paper strips were left to soak for
one hour in the alkaline solution to ensure com-
plete elution. The extracted red color was red in
ililger Spekker using the Ilford green filter. Serum
total proteins were estimated by the method of
Greenberg (24).
Blood serum samples of ten different cases of
vitiligo (before and after treatment with psoralen)
that were analyzed by the previously mentioned
method, were intentionally repeated using an ap-
paratus similar to that mentioned before and
sheets of Whatman No. 1 filter paper 30 x 28 ems.
This allowed simultaneous analysis of many sam-
ples under the same conditions. One mieroliter of
each serum specimen was applied homogenously
over a width of 0.5 ems. Veronal buffer pH 8.6
and ionic strength 0.05 M was used. A constant
voltage of 250 volts was maintained for three
hours. The same dye (azocarmine B) was used.
The dyeing, drying and washing technic of the
paper sheet was adopted as described before. The
eleetropherograms were then obtained by scan-
ning the stained strips using a Spinco-Analytrol
unit (25). The demarcation of the various peaks
was carried out by dropping perpendiculars from
the troughs. The absolute amounts of each of the
fractions were calculated from the total protein
content of the samples that were determined
before by the method of Greenberg (24).
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RESULTS
The results obtained are given in Tables I, II,
III, IV, V and VI.
Table I includes five patients (3 females and 2
males) who had extensive vitiligenous patches
distributed all over the body and completely re-
sponded to meladinine therapy with repigmen-
tation of all the vitiligenous areas. The shortest
period was six months in case 3 and the longest
was 15 months in case 2. Cases 3 and 4 in this
table were among the ten cases that were electro-
phoretieally re-analyzed and scanned. The calcu-
lated figures of the different protein fractions oh-
tamed by scanning and those obtained by elution
were more or less the same. Case 3 in Table I had
the serum alpha2-globulin fraction 0.60 gm/100
ml. serum before treatment with psoralens and
at the end of cure it was 0.62 gm/lOU ml. serum,
i.e. it was normal before and after therapy. The
electrophoretic patterns and electropherograms
of this case before and after cure are given in
Figure 1. Case 4 in Table I had serum alpha2-
globulin fraction below normal (0.41 gm/100 ml.
serum) before treatment with oral psoralens and
ultra-violet irradiation and was raised to 0.70
gm/lOU ml. serum after complete cure as evi-
TABLE I
extensive cases of leukoderma that completely
CaseNo.
1
Age
yrs. Sex
D.T.in
M.
Before Treatment After Treatment
T P.
Globulin
—
Albu-
nun T P•
Globulin
Albu-
g b a-i a-i g b a-, a-i
mm
5 F 10 6.80 1.21 0.62 0.41 0.41 4.15 6.93 1.13 0.61 0.66 0.41 4.12
2 12 M 15 6.43 1.61 0.90 0.37 0.32 3.23 6.73 1.63 0.93 0.71 0.29 3.18
3 15 F 6 6.80 1.62 0.88 0.60 0.20 3.50 7.00 1.88 0.86 0.62 0.22 3.42
4 13 F 14 6.50 1.89 0.61 0.41 0.19 3.40 6.60 1.80 0.60 0.70 0.18 3.32
5 14 M 12 7.19 1.69 0.98 0.43 0.29 3.80 7.30 1.63 0.99 0.67 0.26 3.75
Mean 6.74 1.60 0.80 0.44 0.28 3.62 6.91 1.61 0.79 0.67 0.27 3.56
D.T.: Duration of treatment in months; F: Female; M: Male; T.P.: Total proteins; g: gamma;
b: beta; a-,: alpha-2; a-1: alpha-i; (Total proteins, albumin and globulin fractions are expressed in
gm/100 ml serum)
Serum protein fractions in responded to psoralens
TABLE 11
Serum protein fractions in extensive cases of lea koderma that partially responded to the treatment
of psoralens
Before Treatment
Globulin
After Treatment
GlobulinCase No. Sex
T.P. Albu-min
g b a-i a-i
1 22 F 6.96 1.52 0.82 0.39 0.41 3.81
2 25 F 6.21 1.43 0.73 0.56 0.36 3.13
3 18 M 6.68 1.34 0.91 0.49 0.25 3.69
4 20 M 6.79 1.61 0.77 0.36 0.32 3.74
5 42 F 6.21 1.49 0.69 0.60 0.44 2.99
6 37 M 7.09 1.52 0.87 0.38 0.31 4.01
7 8 M 6.94 1.71 0.99 0.35 0.26 3.63
8 12 F 6.78 1.59 0.67 0.63 0.30 3.59
Mean 6.58 1.53 0.81 0.47 0.33 3.57
T.P.
g
7.02 1.62
6.13 1.39
6.89 1.42
6.78 1.57
6.25 1.49
7.10 1.51
6.89 1.66
6.74 1.49
6.72 1.53
b
0.80
0.67
0.98
0.72
0.68
0.83
0.92
0.73
a-i
0.48
0.61
0.56
0.55
0.64
0.49
0.47
0.71
a-,
0.36
0.35
0.27
0.32
0.42
0.33
0.22
0.30
Albu-
min
3.76
3.11
3.66
3.62
3.02
3.94
3.62
3.51
0.79 0.56 0.32 3.53
TABLE III
Serum proteins in extensive cases of leukoderma showing no response to psoralens
Before Treatment After Treatment
Case No. Age Sex Globulin Globulin
T.P. _____________________ Albu- T.P. ______________ Albu-
g b a-i a-i g b a-i a-i
1 22 F 6.73 1.54 0.67 0.37 0.29 3.86 6.95 1.56 0.69 0.46 0.31 3.93
2 14 M 6.60 1.53 0.87 0.41 0.28 3.51 6.86 1.62 0.91 0.43 0.29 3.61
3 18 F 6.83 1.68 0.86 0.46 0.30 3.53 6.69 1.59 0.83 0.41 0.33 3.53
4 20 F 6.89 1.36 0.75 0.59 0.30 3.89 6.71 1.40 0.69 0.65 0.25 3.72
5 22 M 7.10 1.43 0.73 0.58 0.32 4.04 6.93 1.49 0.67 0.52 0.36 3.89
6 22 F 6.65 1.39 0.73 0.43 0.25 3.86 6.59 1.43 0.73 0.46 0.29 3.68
7 19 F 6.53 1.59 0.77 0.33 0.30 3.54 6.48 1.56 0.71 0.39 0.31 3.51
8 25 M 6.90 1.62 0.73 0.51 0.33 3.71 6.71 1.62 0.66 0.43 0.36 3.64
9 40 M 6.82 1.55 0.67 0.46 0.26 3.94 6.65 1.51 0.63 0.46 0.21 3.84
10 24 F 6.66 1.58 0.91 0.39 0.26 3.52 6.64 1.57 0.88 0.37 0.29 3.63
11 48 F 6.75 1.62 0.83 0.44 0.25 3.61 6.73 1.55 0.69 0.54 0.26 3.69
12 29 M 6.84 1.43 0.77 0.46 0.27 3.91 7.18 1.43 0.68 0.62 0.33 4.12
13 52 M 6.98 1.51 0.64 0.60 0.25 3.98 6.81 1.51 0.72 0.53 0.37 3.68
14 40 F 6.94 1.46 0.70 0.44 0.40 3.94 7.47 1.46 0.71 0.59 0.39 4.32
15 32 F 6.34 1.39 0.81 0.34 0.27 3.53 6.68 1.39 0.83 0.36 0.29 3.81
16 30 M 6.61 1.46 0.68 0.59 0.28 3.60 6.60 1.52 0.69 0.52 0.27 3.60
17 18 M 6.60 1.59 0.82 0.50 0.32 3.50 6.97 1.61 0.83 0.59 0.35 3.59
18 27 M 6.76 1.55 0.69 0.40 0.31 3.81 6.54 1.51 0.72 0.43 0.36 3.52
19 18 F 6.35 1.51 0.72 0.35 0.34 3.43 6.15 1.52 0.65 0.41 0.26 3.31
20 20 F 6.68 1.54 0.78 0.41 0.29 3.66 6.33 1.49 0.79 0.33 0.31 3.41
21 14 F 6.77 1.65 0.78 0.44 0.30 3.60 6.77 1.48 0.88 0.39 0.33 3.69
22 11 F 6.83 1.38 0.75 0.47 0.33 3.90 6.88 1.51 0.75 0.51 0.40 3.71
23 14 M 7.16 1.42 0.74 0.48 0.34 4.18 7.10 1.60 0.74 0.44 0.42 3.90
24 17 M 6.85 1.65 0.76 0.39 0.36 3.69 7.19 1.79 0.71 0.42 0.39 3.88
25 16 F 6.53 1.39 0.81 0.54 0.27 3.53 6.48 1.33 0.92 0.49 0.25 3.49
26 25 M 6.87 1.50 0.75 0.44 0.33 3.85 7.04 1.48 0.81 0.67 0.29 3.79
Mean 6.75 1.51 0.76 0.46 0.30 3.73 6.78 1.52 0.75 0.48 0.32 3.70
T.P.: Total proteins; g: Gamma; b: Beta; a-2: Alpha-2; a-1: Alpha-i; (Total proteins, albumin and
globulin fractions are expressed in gm/100 ml serum)
TABLE IV
Serum protein fractions in localized cases of vitiligo that completely responded to psoralens
Before Treatment After Treatment
nT.
Case No. ge Sex in Globulin Globulin
M. T.P. Albu- T.P. Albu-min mm
g b a i a-i g b a-i a-i
1 42 M 12 6.71 1.46 0.67 0.47 0.31 3.80 6.80 1.41 0.68 0.63 0.39 3.69
2 18 F 3 6.78 1.53 0.69 0.63 0.32 3.61 6.91 1.45 0.73 0.72 0.41 3.60
3 22 F 16 6.81 1.49 0.83 0.51 0.25 3.73 7.02 1.53 0.77 0.81 0.20 3.71
4 27 F 14 6.93 1.62 0.91 0.49 0.29 3.62 7.20 1.70 0.88 0.59 0.33 3.70
5 30 M 9 6.86 1.73 0.72 0.56 0.26 3.59 6.70 1.66 0.75 0.60 0.30 3.49
6 32 M 5 6.40 1.41 0.66 0.74 0.25 3.34 6.37 1.36 0.67 0.73 0.29 3.32
7 12 F 6 6.22 1.33 0.59 0.53 0.33 3.44 6.39 1.39 0.62 0.66 0.31 3.41
8 7 M 6 6.38 1.44 0.73 0.57 0.35 3.29 6.39 1.40 0.70 0.65 0.32 3.32
9 14 F 8 6.30 1.54 0.88 0.53 0.21 3.14 6.59 1.59 0.80 0.75 0.25 3.20
Mean 6.61 1.51 0.74 0.56 0.29 3.51 6.70 1.49 0.73 0.68 0.31 3.49
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TABLE V
Serom protein fractions in localized cases of vitiligo that showed partial response to psoralens
Before Treatment
Globulin
After Treatment
T.P.
Age
yrs.
30
22
28
56
18
28
30
20
60
Case No.
1
2
3
4
5
6
7
8
9
Mean
Sex
F
F
M
M
M
F
F
F
M
Globulin
T.P.
7.04
6.99
6.79
6.52
6.78
6.80
6.54
6.79
6.74
g
1.40
1.76
1.53
1.36
1.44
1.86
1.71
1.73
1.63
b
0.69
0.77
0.67
0.81
0.89
0.70
0.72
0.77
0.73
a-,
0.39
0.52
0.38
0.44
0.51
0.37
0.68
0.49
0.51
a-i
0.27
0.39
0.33
0.22
0.33
0.26
0.27
0.30
0.36
4.29
3.55
3.89
3.69
3.61
3.61
3.21
3.50
3.51
7.31
7.21
6.93
6.62
6.91
6.86
6.65
6.70
6.98
g
1.45
1.86
1.46
1.36
1.42
1.82
1.73
1.69
1.77
b
0.64
0.72
0.70
0.82
0.91
0.63
0.67
0.72
0.71
Albu-
min
4.38
3.63
3.94
3.64
3.71
3.52
3.31
3.42
3.51
a-i
0.28
0.41
0.35
0.28
0.31
0.25
0.29
0.34
0.39
a-,
0.56
0.59
0.49
0.52
0.56
0.64
0.65
0.53
0.60
0.586.77 1.61 0.75 0.47 0.30 3.65 6.91 1.62 0.72
TABLE VI
Serum protein fractions in localized cases of vitiligo showing no response to psoralens
0.32 3.67
Before Treatment
Globulin
After Treatment
b a-i a-i
T.P.
Globulin
g b a-, a-i
30
42
45
12
43
22
32
15
18
21
12
14
46
15
23
24
19
41
51
45
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Mean
F
M
F
M
M
M
F
M
M
F
M
M
F
M
F
F
F
M
F
M
g
1.61
1.98
1.64
1.37
1.74
1.70
1.61
1.49
1.54
1.35
1.45
1.39
1.63
1.81
1.73
1.64
1.39
1.41
1.67
1.76
7.32
7.12
6.72
6.79
6.94
7.29
6.74
6.77
6.61
6.63
6.63
6.41
6.50
6.94
7.07
6.64
6.93
6.67
6.66
6.29
6.73
0.75
1.04
0.69
0.96
0.73
0.68
0.59
0.91
0.85
0.83
0.66
0.71
0.67
0.63
0.81
0.83
0.74
0.80
0.71
0.70
0.42
0.33
0.35
0.56
0.44
0.51
0.45
0.60
0.43
0.39
0.58
0.52
0.39
0.42
0.76
0.44
0.55
0.52
0.61
0.49
0.22
0.28
0.32
0.36
0.21
0.29
0.35
0.28
0.27
0.33
0.32
0.38
0.42
0.26
0.30
0.36
0.26
0.25
0.31
0.22
4.23
3.59
3.72
3.64
3.82
3.91
3.74
3.49
3.52
3.73
3.62
3.41
3.39
3.82
3.47
3.37
3.99
3.69
3.36
3.12
7.17
7.06
6.92
7.03
7.04
7.02
6.70
7.07
6.51
6.68
6.70
6.51
6.54
7.07
7.03
6.63
6.81
6.75
6.50
6.26
1.58
1.90
1.69
1.41
1.71
1 .59
1.49
1 .57
1.39
1.39
1.52
1.43
1.70
1.72
1.77
1.70
1.28
1.45
1.59
1.78
0.77
0.97
0.72
0.99
0.72
0.69
0.65
0.96
0.85
0.92
0.67
0.73
0.67
0.69
0.76
0.82
0.73
0.80
0.76
0.71
0.36
0.40
0.42
0.60
0.43
0.69
0.45
0.63
0.40
0.36
0.58
0.48
0.36
0.44
0.79
0.45
0.58
0.46
0.65
0.50
0.25
0.28
0.31
0.32
0.26
0.25
0.30
0.29
0.33
0.31
0.21
0.36
0.38
0.33
0.34
0.36
0.31
0.30
0.29
0.21
Albu-
min
4.17
3.61
3.78
3.71
3.93
3.80
3.81
3.60
3.41
3.70
3.72
3.51
3.43
3.89
3.37
3.30
3.91
3.74
3.41
3.06
3.631.60 0.71 0.49 0.30 3.63 6.80
T.P.: Total proteins; g: gamma; b: beta; a-,: alpha-,; a-,: alpha-,; (Total proteins, albumin and
globulin fractions are expressed in gm/100 ml serum)
1.59 0.78 0.50 0.31
— 6tf.rtTrIt*.w*Rt.
Af*tP Curt.
116 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
deneed by the full repigmentation of all the
vitiligenous patches. The eleetrophoretie patterns
and eleetropherograms of this ease before and
after treatment are given in Figure 2.
Table II represents eight patients (4 males and
4 females) with extensive vitiligo that responded
to oral psoralens and ultra-violet irradiation by
partial repigmentation although the treatment
was maintained for 24 months.
Table III represents 26 patients (14 females
and 12 males) with extensive vitiligo that did not
respond to oral psoralens and ultra-violet ir-
radiation.
Table IV represents nine patients (5 females
and 4 males) that had localized vitiligo and re-
sponded completely to oral psoralens and ultra-
violet irradiation. The shortest period of treat-
ment in this group was 3 months in ease 2 and
the longest period was 16 months in ease 3.
Table V represents nine patients (5 females
and 4 males) with localized vitiligo that partially
responded (i.e. partial repigmentation of some of
the patches) to oral psoralens and ultra-violet
irradiation in spite of the continuation of therapy
for the allotted treatment period.
Table VI represents twenty patients (9 females
and 11 males) who did not respond to oral
psoralens and ultra-violet irradiation, although
they were kept under treatment for the two years
treatment.
FIG. 1. Eleetrophoretie patterns and electro-
pherograms (of Case 3, Table 1) before treatment
and after cure with psoralens. (Alpha1 serum
globulin fraction normal before and after.)
FIG. 2. Eleetrophoretie patterns and eleetro-
pherograms (of Case 4, Table I) before treatment
and after cure with psoralens. (Alpha2 serum
globulin fraction low before treatment and normal
after cure.)
There was no incidence of either albuminuria
or glyeosuria in any of the eases studied during
the whole period of treatment. No toxic effects
of psoralens on the liver could be detected in this
long study. All liver function tests were normal
and there was never any clinical evidence of liver
derangement.
DISCUSSION
Eleetrophoretie study of serum proteins of 77
eases of vitiligo was carried out before and during
a 3 to 24 month period of treatment with pso-
ralens (ammoidin and ammidin) plus ultra-violet
irradiation. Before starting treatment the serum
total proteins, albumin, alpha1, beta and gamma
globulins were found to be within the normal
limits for Egyptians, (26, 27) whereas the serum
alpha2-globulin fraction was found to be below
the normal level in 40 eases (i.e. 52%) and within
normal limits in 37 eases (i.e. 48%) of the total
number of the eases studied.
Fourteen patients (i.e. 18%) were cured com-
pletely. Five had extensive vitiligo, and their
serum alpharglobulin fraction was raised under
treatment with oral psoralens from a mean value
of 0.45 to 0.67 gm/100 ml. serum. Nine patients
had localized vitiligo, and their serum alphar
globulin fraction was also raised from a mean
value of 0.56 to 0.68 gm/100 ml. serum.
Seventeen patients (i.e. 22%) showed partial
improvement as shown by complete, partial and
a • —
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no repigmentation of the various affected vitilige-
nous areas in the same patient. The progress
came to a standstill although treatment was con-
tinued for the entire 24 months period. Eight out
of these were extensive and nihe cases were
localized. In the former group the serum alphar
globulin was raised under treatment with pso-
ralens from a mean value of 0.47 to 0.56 gm/100
ml. serum and in the latter group the serum
alpharglohulin was raised from a mean of 0.47 to
0.58 gm/100 ml. serum, at the end of the 24
months. period of therapy and observation.
Forty-six patients (26 extensive and 20 local-
ized) i.e. 60% of the total number of cases of
vitiligo studied did not show any response to the
combined oral psoralens and ultra-violet treat-
ment.
It has been observed that a group of the cured
cases had normal serum alpha2-globulin before
psoralen treatment and they responded quickly
to psoralen therapy and ultra-violet irradiation
within a period of 3 to 6 months. The cured
cases with low serum alpha2-globulin responded
more slowly (from 6 to 16 months) to therapy.
Those cases that did not show any response to
psoralens and ultra-violet rays through the whole
treatment period could be divided into two
groups: a group with normal serum alphar
globulin and the other with serum alpha2-globulin
below the normal level.
The cases that were completely or partially
cured under psoralens and ultra-violet irradiation
and in whom the serum alpharglobulin fraction
was low before treatment and came up to normal
values after treatment seem to run parallel with
the findings of El-Mofty, El-Hawary and Farag
(9, 28), who have shown that some patients with
vitiligo had low serum copper before treatment
and when cured with psoralens had a serum
copper elevation to normal—probably because
copper is incorporated into ceruloplasmin which
is associated with serum alpharglobulin frac-
tion. This concomitant increase in serum alpha2-
globulin and serum copper is evidenced by
the fact that copper is incorporated in eerulo-
plasmin molecule in vivo only at the time of its
synthesis and not through exchange of ionic
copper (18). The action of psoralens is probably
not only through mobilization of copper from the
liver as postulated by El-Mofty el al (29, 30), but
it also may play a role in the incorporation of
copper into the protein to form ceruloplasmin.
This may explain the rapid cure in cases with
normal serum alpha2-globulin and normal serum
copper.
Our findings in the group of vitiligenous
patients who before treatment had a low serum
alpha2-globulin levels and whose levels remained
low in spite of the enthusiastic treatment with
psoralens and ultra-violet irradiation parallel the
findings of El-Mofty et al (9, 28) who have noted
that some of their vitiligenous patients with low
serum copper did not get an increase in serum
copper or clinical improvement with treatment
with psoralens and ultra-violet irradiation.
The third group of cases in our series who had
normal serum alpharglobulin fraction before
treatment with psoralens and who did not respond
to therapy is analogous to that group of cases
reported by El-Mofty et at (9, 28) with normal
copper level and no response to psoralen therapy.
In these eases it would appear that the loss of
pigmentation is probably due to factors other
than copper deficiency. Among the factors to be
considered are a deficiency in the substrate
tyrosine, an abnormal excessive inhibition by the
sulfydryl groups (31), a defect in the process of
linkage of copper to the apoenzyme in the
tyrosinase system to render it active or lack of
certain vitamins that are of great value in the
process of pigmentation. Pantothenic acid (32)
may be involved in the linkage of copper to the
apotyrosinase to render it active. Ascorbic acid
is a maj or factor in maintaining sulfydryl level in
tissues and blood (33). Paraminobenzoie acid
(34, 35), biotin (36, 37), and folic acid (38) are
important factors in melanin formation since the
proper utilization of panthothenie acid is in some
way dependent on their presence (39).
Holmberg (40) detected hemocuprin in blood,
4 molecules of which combine to form one of
eeruloplasmin. Psoralens may indeed play a role
in this combination.
Further investigation of eeruloplasmin in serum
of psoralen treated vitiligo patients with labelled
copper in eases of low and of normal serum
copper may throw further light on the etiology
of the disease.
SIJMMAEY
(1) Eleetrophoretic studies on serum proteins
of 77 selected eases of vitiligo were carried out
before and after treatment with psoralens and
ultra-violet irradiation.
(2) Serum total proteins, albumin, alpha!, beta
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and gamma globulin fractions were found within
the normal range before and after treatment.
(3) Serum alpha2-globulin was below the nor-
mal level in 52% and within normal limits in
48% of the eases.
(4) Under psoralens treatment, 18% were cured
completely and had serum alpha2-globulin ele-
vated to normal levels, 22% were partially cured
and had serum alpha2-globulin slightly increased,
approaching low normal values, and 60% demon-
strated neither clinical improvement nor serum
protein alteration.
(5) Patients who responded quickly to treat-
ment with psoralens had relatively normal serum
alpharglohulin fractions, whereas patients who
responded over a long treatment period had
markedly low alpharglobulin fractions.
(6) The significance of these findings is dis-
cussed.
REFERENCES
1. FAnnY, I. R. AND AND-SHADY, H.: Ammi
Majus Linn, pharmacognostical study ofisolation of a crystalline constituent,
ammoidin. Quart. J. Pharm. & Parmacol.,
20: 281, 1947.
2. FAHMY, I. R. AND AND-SHADY, H., The isola-
tion and properties of ammoidin, ammidin
and majudin, and their effect in the treat-
ment of leueoderma. Quart. J. Pharm. and
Pharmaeol., 21: 499, 1948.
3. FAHMY, I. R., AND-SHADY, H., ScHöNBaRo,
A. AND SINA, A.: A crystalline principle from
Ammi Majus Linn. Nature, 160: 468, 1947.
4. SCHoNBERo, A. AND SINA, A.: Xanthotoxin
from the fruits of Ammi Majus Linn. Nature,
161: 481, 1948.
5. EL-HEFNAwI, H.: A preliminary clinical
report on the treatment of leucoderma with
meladinine tablets and meladinine paint.
Trudean Rev, for Med. Researches, 3:
1—4, 1950.
6. EL-MOFTY, A. M.: Further studies on the
treatment of leueoderma with Ammi Majus
Linn. J. Roy. Egypt. Med. Ass., 35: 1, 1952.
7. SEKLA, M.: Treatment of vitiligo. A.M.A.
Arch. Dermat. & Syph., 65: 358—359, 1952.
8. Sini, E. AND BOURGEOI5-GAvARDIN, J.:
Mise au point du traitement du Vitiligo
par "L'Ammi Majus" Presse Med., 61:
436—440, 1953.
9. EL-MOFTY, A. M., EL-HAWARY, M. F. S. AND
FARAD, F. B.: The estimation of serum
copper and blood glutathione in vitiligenous
patients under the effect of psoralen treat-
ment. J. Egypt. Med. Ass., 44: 124, 1961.
10. EL-MOFTY, A. M.: New clinical findings in the
treatment of leueoderma. The effect of addi-
tion of copper to psoralen treatment. Aeta
Dermatovener., 1957—58. Devoted to the
11th International Congress of Dermat.
Stockholm.
11. MANN, T. AND KEILIN, D.: Haemocuprein and
hepatocuprein, copper protein compounds
of blood and liver in mammals. Proc. Roy.
Soc., B., 126: 303, 1938.
12. THOMPSON, R. H. S. AND WATsON, D.: Serum
copper levels in pregnancy and in pre-
eelampsia. J. Clin. Path., 2: 193—196, Aug.
1949.
13. CmejNos, J. N., C00DwIN, H. J. AND EARL,
C. J.: Blood copper and its relationship to
globulins. J. Clin. Path., 8: 69—72, Feb. 1955.
14. Ku0ELMA55, I. N.: Biochemistry of Blood in
Health and Disease. Publication No. 348
American Lecture Series. p. 208. Illinois,
U.S.A., Charles C Thomas Publishers, 1959.
15. DUNCAN, C. G.: Diseases of Metabolism. p.
251, 1960. W. B. Saunders Company Fourth
Edition, 1959. Reprint Feb. 1960.
16. CURLER, C. J., LAHEY, M. E., CARTWRIOHT,
C. E. AND WINTROBE, M. M.: Copper me-
tabolism. IX. The transportation of copper
in blood. J. Clin. Invesl., 32: 405, 1953.
17. SCHEINBEEG, I. H. AND STERNLIEB, I.: Copper
metabolism. Pharmaeol. Rev., 12: 355, 1960.
18. STERNLIEB, I., MORELL, A. G., TUcKER,
W. D., GREENE, M. W. AND SCHEINBEEO,
I. H.: The incorporation of copper into
eeruloplasmin in vivo: Studies with Cu64
and Cu67. J. Clin. Invest., 40: 1834, 1961.
19. EL-HEFNAWI, H., EL-NABAWv, M. AND EL-
HAWARY, M. F. S.: Serum copper and blood
glutathione in 12 eases of xeroderma pig-
mentosum. Brit. J. Derm., 74: 218, 1962.
20. EL-HEFNAwI, H., EL-NABAWY, M. AND
EL-HAwARY, M. F. S.: Electrophoretie
studies of xeroderma pigmentosum. Brit. J.
Derm., 74: 214, 1962.
21. BROWN, T.: Eleetrophoretie analysis of serum
proteins in pregnancy. Preliminary report.J. Obstet. Cynaecol. Brit. Emp., 61: 781,
1954.
22. KUHN, W. J. AND HvLAND, P. J.: Zone eleetro-
phoresis in studies of maternal and fetal
sera. Proc. Soc. Exp. Biol. Med., 92: 1—4,
1956.
23. DUEBAM, E. L.: Continuous eleetrophoresis
and ionophoresis on filter paper. J. Amer.
Chem. Society, 73: 4875, 1951.
24. CEEENBERO, D. M.: The eolorimetrie determi-
nation of the serum proteins. J. Biol. Chem.,
82: 545, 1929.
25. OIR-1 Spineo Model R Instruction Manual.
Spineo Division, Beckman Instruments
Inc., Belmont, California.
26. EL-CHOLMv, A., EL-NABAwY, M., SHOUEBY,
S., ISMAIL, SOBAYA AND EL-HAWARY, M. F. S.:
Biochemical studies on serum proteins in
kwashiorkor of Egyptian infants. J. Trop.
Med. Hyg., 63: 137, 1960.
27. EL-HAWAEv, M. F. S. AND FATMA HA55AN:
Eleetrophoretic studies on serum proteins
after antirabies vaccine administration.
J. Trop. Med. Hyg., 64: 121, 1961.
28. EL-MOFTY, A., EL-HAWAEv, M. F. S. AND
FARAD, F. B.: The estimation of serum
copper and blood glutathione in normal
and vitiligeuous persons. J. Egypt. Med.
Assoe., 44: 13, 1961.
29. EL-MOFTY, ANwAR, EL-MOFTv, ABDEL
MONEM, ABDELAL, H. AND EL-HAwARY,
M. F. S.: Studies on the mode of action of
psoralen derivatives. I. Their effect on
copper and glutathione levels in blood and
liver. Jour. Invest. Derm., 32: 645, 1959.
ANNOUNCEMENTS 119
30. EL-MOFTY, ANWAR, EL-MOFTY, ABDEL
MONEM, ABDELAL, H. AND EL-HAWARY,
M. F. S.: Studies on the mode of action of
psoralen derivatives. II. The pituitary
adrenal axis control of copper metabolism
and its response to psoralens. J. Invest.
Derm., 32: 651, 1959.
31. LERNEa, A. B., DENTON, C. A. AND FITZ-
PATRICK, T. B.: Clinical and experimental
studies with 8-Methoxypsoralen in vitiligo.
J. Invest. Derm., 20: 299, 1953.
32. SINGER, L. AND DAVIS, C. K.: Pantothenic
acid in copper deficiency in rats, Science,
Vol. III: 472, 1950.
33. LERNER, A. B. AND FITZPATaICK, T. B.:
Biochemistry of melanin formation. Physiol.
Rev., 30: 91, 1950.
34. MARTIN, C. J. AND ANSBACHER, S.: Confirma-
tory evidence of the chromotrichial activity
of p-aminobenzoic acid. J. Biol. Chem..
138: 441, 1941.
35. ANsBACHEa, S.: p-aminobenzoic acid. Experi-
mental and clinical studies. Vitamins
Hormones, 2: 215—254, 1944.
36. SULLIVAN, M. AND NICH0LLI5, J.: The nutri-
tional approach to experimental derma-
tology. Nutritional dermatoses in the rat
vit. B6 deficiency. J. Invest. Derm., 3:
317, 1940.
37. EMERSON, C. A. AND KERESZTRSE, J. C.:
Biotin deficiency in the rat. Proc. Soc. Exp.
Biol. Med., 51: 358, 1942.
38. FROST, D. V., DANN, F. P. AND MCINTIRE,
F. C.: Adequacy of the known synthetic
vitamins for normal feathering and pigmen-
tation in chicks. Ibid., 61: 65, 1946.
39. WRIGHT, L. D. AND WELCH, A. D.: Folic acid,
biotin cud pantothenic acid deficiency and
the liver storage of various vitamins in
rats fed succinylsulphathiazole in highly
purified rations. J. Nutr., 27: 55, 1944.
40. HOLMEERG, C. G. AND LALTRELL, C. B.: In-
vestigations in serum copper. Part III.
Ceruloplasmin as an enzyme. Acta Chem.
Scand., \Tol 5: 476, 1951.
ANNOUNCEMENTS
Annual Essay Contest
The Chicago Dermatological Society is sponsoring an Essay Contest with
three prizes of $500, $300, and $200.00. The essay, not previously published,
must be on some phase of dermatology or in the fundamental sciences relative
to a dermatologic problem.
Competition is open to members and accredited guests of the Chicago Derma..
tological Society, and all those scientists working within the Middle Western
States who are sponsored, in writing, by a member.
All manuscripts must be typed in English, double-spaced, and with ample
margins as required for publication. Three copies of each manuscript, together
with illustrations, charts and tables are to be submitted to the Secretary of the
Chicago Dermatological Society not later than April 15, 1963. Manuscripts
should be limited to 10,000 words or less.
Further information regarding the contest may be obtained by writing to the
Secretary, Frederick D. Malkinson, M.D., 950 E. 59th Street, Chicago 37, Ill.
SCIENTIFIC ExHImTs.—Applications are now being received for space for scien-
tific exhibits at the meeting of the American Academy of Dermatology at the
Palmer House, Chicago, in December, 1963.
Awards will be given for the best exhibits in each of the following categories:
(2) Teaching value
Please address all correspondence before the application deadline, June 1, 1963,
to Frederick D. Malkinson, M.D., Section of Dermatology, The University of
Chicago Hospitals and Cliuics, 940 E. 59th Street, Chicago 37, Illinois.
(1) Original investigation (3) Historical
